RT Journal Article
SR Electronic
T1 Cell-Free DNA GWAS Reveals Importance of p.Arg206Cys in DNASE1L3 for Non-Invasive Testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.15.24312005
DO 10.1101/2024.08.15.24312005
A1 Linthorst, Jasper
A1 Nivard, Michel
A1 Sistermans, Erik A.
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.15.24312005.abstract
AB Properties of cell-free DNA (cfDNA) are intensely studied for their potential as non-invasive biomarkers. We explored the effect of common genetic variants on concentration and fragmentation properties of cfDNA using a GWAS based on low-coverage whole genome sequencing data of 140.000 Dutch Non-Invasive Prenatal Tests (NIPT). Our GWAS detects many genome-wide significant loci, functional enrichments for Phagocytes, Liver, Adipose tissue, Macrophages and genetic correlations with autoimmune and cardiovascular disease. A common (7%) missense variant in DNASE1L3 (p.Arg206Cys), strongly affects all cfDNA properties. It increases the size of fragments, lowers cfDNA concentrations, affects the distribution of cleave-site motifs and increases the fraction of circulating fetal DNA during pregnancy. For the application of NIPT, and potentially other cfDNA-based tests, this variant has direct clinical consequences as it increases the odds of inconclusive results and impairs the sensitivity of NIPT by causing predictors to overestimate the fetal fraction.HIGHLIGHTSCommon variants affect properties of plasma cell-free DNAp.Arg206Cys in DNASE1L3 strongly affects the size of cell-free DNA fragmentsFragmentomics-based fetal fraction predictors are affected by p.Arg206CysGenetics behind cfDNA overlaps with autoimmune and cardiovascular diseasesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a grant from the Netherlands Organization for Health Research and Development (ZonMw, No. 543002001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethics Review Committee of VU University Medical Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors